Patent Application
20080095867
The present invention is in relation to combination herbal compositions for therapeutic use, wherein said compositions comprise of extracts containing hydroxycitric acids and anthocyanins from Garcinia and Hibiscus species, optionally along with healthful or therapeutics second agents, and pharmaceutically acceptable additives.
Hibiscus is also known as the “Roselle” flower a common name from German usage. Apart from the German “roselle”, the plant is known by numerous common names, including the French “karkadé” (red tea) the That “krachiap daeng”, the Persian “sour tea”, the Chinese “Lo Shen”, and the English “Roselle of Rama”, “Jamaica sorrel”, “Indian sorrel”, “jelly okra”, “sour-sour Queensland jelly plant”, and “Florida cranberry”.
These compositions in the form of various permutations and combinations of the extracts show additive or synergistic therapeutic activity with respect to the activities of the respective individual constituents. The details of preferred compositions as six therapeutic embodiments of the invention are provided in the table below.
The present disclosure provides, among other things, combination herbal compositions for therapeutic use, wherein said compositions comprise of extracts containing hydroxycitric acids and anthocyanins from Garcinia and Hibiscus species, optionally along with healthful or therapeutics second agents, and pharmaceutically acceptable additives.
These compositions in the form of various permutations and combinations of the extracts show additive or synergistic therapeutic activity with respect to the activities of the respective individual constituents. The details of preferred compositions as six therapeutic embodiments of the invention are provided in the table below.
Hibiscus sabdariffa extract:- not less than 45% (+) HCA + 0.1 to
The present invention is in relation to combination herbal compositions for therapeutic use, wherein said compositions comprise of extracts containing hydroxycitric acids and anthocyanins from Garcinia and Hibiscus species, optionally along with healthful or therapeutics second agents, and pharmaceutically acceptable additives.
These compositions in the form of various permutations and combinations of the extracts show additive or synergistic therapeutic activity with respect to the activities of the respective individual constituents. The details of preferred compositions as six therapeutic embodiments of the invention are provided in the table below.
Hibiscus sabdariffa extract:- not less than 45% (+) HCA + 0.1
In some embodiments of the present invention, the extract comprises of 45%-75% of Hydroxycitric acid and 0.1 to 30% anthocyanins.
Some embodiments include delphinidin 3-sambubioside and in the anthocyanin fraction. Delphinidin 3-sambubioside constitutes in the range of about 70% of the anthocyanins; cyanidin 3-sambubioside and other cyanidin and delphinidin glycosides may also be present. These two species account for a significant portion of the antioxidant activity obtained in the Hibiscus extracts.
In at least one embodiment of the present invention, the hydroxycitric acid is metal salt. In other embodiments of the present invention, the metals are selected from a group comprising IA and IIA group metals of the periodic table.
In at least one embodiment of the present invention, the ratio of hydroxycitric acid salts and anthocyanins is ranging from 70:30 and 99:1.
In yet other embodiments of the present invention, the ratios of the relative presence of (−) HCA, (+) HCA, and the anthocyanins are adjusted in order to optimize the inhibition of alpha amylase. In various embodiments, the concentrations of each of the constituents of embodiments of the composition are adjusted independently of each other, in order to provide particular or maximal therapeutic benefits.
In some embodiments of the present invention, the further or secondary agents are selected from a group comprising mangosteen, pomegranate, blueberries, grape seed, red bush, banaba, green tea, L-carnitine, chromium, caffeine, and vitamins.
In some embodiments of the present invention, the pharmaceutically acceptable additives are selected from a group comprising granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents and spheronization agents.
In some embodiments of the present invention, the therapeutic uses are obesity, hyperlipediemia, and any conditions for which suppression of appetite may provide healthful or therapeutic benefit. In a therapeutic manner, thus, patients or subjects suffering from these or related disorders are provided the therapeutic composition. In some embodiments, the compositions are administered as a beverage.
The present invention relates to processes for the preparation of combinational herbal compositions in at least some of the embodiments, such processes comprising steps of extracting hydroxycitric acids and anthocyanins from Garcinia and Hibiscus species, reacting the hydroxycitric acid with IA and IIA group metals of periodic table, isolating one or more salts of hydroxycitric acid, blending with anthocyanins from Hibiscus, and drying to obtain the therapeutic composition.
The present invention relates to use of compositions comprising extracts of hydroxycitric acid and anthocyanins from Garcinia and Hibiscus species optionally along with secondary agents and pharmaceutically acceptable additives to manufacture a medicament for multiple therapeutic uses.
The present invention further relates to providing therapeutic and dietary compositions in appropriate formulations, with excipients and coatings that support optimal and appropriate delivery and general bioavailability of the active agents of the compositions. Excipients may include granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, and spheronization agents.
In some embodiments, nanotechnological approaches to controlling particle size, to the range of 20 microns, for example, and controlling surface features of the particles, all of which are directed toward increasing the bioavailability of such embodiments.
The technology of the present application is further elaborated with the following examples; these are provided for clarification of the invention, and should not be construed to limit the scope of the invention.
1. Water or Hydro Alcohol extract of Hibiscus dried calyces, including three extractions with four volumes of solvent.
2. Combine all the three extracts (Extract #1), filter, concentrate, and dry to yield Product #1:
3. Load Extract #1 onto a weak anion column.
4. Wash the column with DM Water to remove the pigments.
5. Elute with sodium hydroxide solution.
6. Load the eluent onto a strong cation column.
7. Collect all the free acid (Extract #2).
8. Load Extract #1 onto a macroporous non ionic resin.
9. Collect the unadsorbed eluent, and wash the column with water.
10. Combine the eluent and washings (Extract #3).
11. Load the Extract #3 onto a weak anion column.
12. Wash the column with DM water to remove the pigments.
13. Elute with sodium hydroxide solution.
14. Load the eluent onto a strong cation column.
15. Collect all the free acid (Extract #4).
16. Bleach Extract #2 and/or Extract #4 with charcoal.
17. Filter the extract to remove charcoal (Extract #5).
18. React the Extract #5 with magnesium and potassium.
19. Concentrate and dry, to yield Product #2A:
20. React the Extract #5 with calcium and potassium. Refer also to Note 1, below, regarding other salts of (+) HCA.
21. Concentrate and dry, to yield Product #2B:
22. Concentrate the Extract #5 to 60% total solids, to yield Product #2C (liquid (+) HCA, not as a salt):
23. Elute the Nonionic resin column with hydro alcohol.
24. Concentrate the eluent and dry to yield Product #3:
25. Combine Product #2A, 2B, or 2C with Product #4 (Product #4).
26. Water/Hydro Alcohol extract of Garcinia cambogia dried fruit rind. (Four extractions with six volumes of solvent.) Combine all the four extracts (Extract #6).
27. Load Extract #6 onto a weak anion column.
28. Wash the column with demineralized (DM) water to remove the pigments.
29. Elute with sodium hydroxide solution.
30. Load the eluent onto a strong cation column.
31. Collect all the free acid, and bleach the extract with charcoal.
32. Filter the extract to remove charcoal (Extract #7).
33. Combine Extract #5 and Extract #7 in the ratio 10%:90% to 90%:−10%, to yield Extract #8.
34. React the Extract #8 with magnesium and potassium.
35. Concentrate and dry (Product #5A) Mixture of (+) HCA and (−) HCA DDM Salt.
36. React the Extract #8 with calcium and potassium.
37. Concentrate and dry (Product #5B). Note 1, other salts of a mixture of (+) HCA and (−) HCA.
38. Concentrate the Extract #8 to 60% total solids, to yield (Product #5C) liquid of a mixture of (+) HCA and (−) HCA, not as a salt.
In Example Two and other embodiments of the present invention, any of the IIA group metal, including but not limited to Be, Mg, Ca, Sr, Ba, or Ra; and any IA group metal including but not limited to Li, Na, K, Rb, Cs, or Fr can be used. The above data in the product #2A, 4A, 5A, 6A is for a specific Mg/K salt. Any of the above metals can be used to give salts as any double metal salt, tri metal salt or even tertiary metal salt as monomers, dimers, trimers, etc., and esters of (−) HCA and/or (+) HCA, as applicable.
While the apparatus and method have been described in terms of what are presently considered to be the most practical and preferred embodiments, it is to be understood that the disclosure need not to be limited to the disclosed embodiments. It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar structures. The present disclosure includes any and all embodiments of the following claims.
This application claims the benefit of and priority to U.S. Provisional Application Ser. No. 60/862,171, filed Oct. 19, 2006, the contents of which are incorporated by reference herein in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 60862171 | Oct 2006 | US |
